or Try an Advanced Search...

    Technical Analysis for ABVC - ABVC Biopharma, Inc.

    Grade Last Price % Change Price Change
    F 0.82 5.93% 0.05
    ABVC closed up 5.93 percent on Monday, July 1, 2024, on 19 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical ABVC trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Up 3 Days in a Row Strength 0.00%
    Narrow Range Bar Range Contraction 11.26%
    NR7 Range Contraction 11.81%
    Narrow Range Bar Range Contraction 11.81%
    Inside Day Range Contraction 11.81%
    Oversold Stochastic Weakness 10.16%
    MACD Bullish Signal Line Cross Bullish 8.02%
    Stochastic Buy Signal Bullish 8.02%
    Gapped Up Strength 8.02%
    Older End-of-Day Signals for ABVC ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 9 hours ago
    20 DMA Resistance about 9 hours ago
    Up 3% about 9 hours ago
    Down 1% about 9 hours ago
    Up 2% about 9 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ABVC Chart by TradingView
    Basic chart:

    Profile

    ABVC Biopharma, Inc. Description

    American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Pancreatic Cancer Depression Major Depressive Disorder Myelodysplastic Syndrome Attention Deficit Hyperactivity Disorder Treatment Of Pancreatic Cancer Triple Negative Breast Cancer

    Is ABVC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 25 ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
    Jun 21 ABVC Biopharma files to sell 1M shares of common stock for holders
    Jun 12 ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
    May 24 Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M
    May 22 ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M
    May 15 Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M
    May 9 Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
    Apr 18 AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
    Apr 17 ABVC BioPharma executes licensing agreement with OncoX
    Apr 17 ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
    See more ABVC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.87
    52 Week Low 0.697
    Average Volume 707,022
    200-Day Moving Average 1.16
    50-Day Moving Average 0.98
    20-Day Moving Average 0.78
    10-Day Moving Average 0.75
    Average True Range 0.06
    RSI (14) 48.19
    ADX 19.06
    +DI 24.61
    -DI 24.41
    Chandelier Exit (Long, 3 ATRs) 0.73
    Chandelier Exit (Short, 3 ATRs) 0.87
    Upper Bollinger Bands 0.87
    Lower Bollinger Band 0.69
    Percent B (%b) 0.72
    BandWidth 22.23
    MACD Line -0.06
    MACD Signal Line -0.07
    MACD Histogram 0.014
    Fundamentals Value
    Market Cap 6.49 Million
    Num Shares 7.91 Million
    EPS -3.57
    Price-to-Earnings (P/E) Ratio -0.23
    Price-to-Sales 14.34
    Price-to-Book 1.13
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.92
    Resistance 3 (R3) 0.91 0.87 0.90
    Resistance 2 (R2) 0.87 0.84 0.87 0.89
    Resistance 1 (R1) 0.84 0.83 0.86 0.85 0.89
    Pivot Point 0.80 0.80 0.81 0.81 0.80
    Support 1 (S1) 0.78 0.78 0.79 0.79 0.75
    Support 2 (S2) 0.74 0.77 0.74 0.75
    Support 3 (S3) 0.72 0.74 0.74
    Support 4 (S4) 0.72